<SEC-DOCUMENT>0001654954-20-011251.txt : 20201019
<SEC-HEADER>0001654954-20-011251.hdr.sgml : 20201019
<ACCEPTANCE-DATETIME>20201019080116
ACCESSION NUMBER:		0001654954-20-011251
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20201006
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20201019
DATE AS OF CHANGE:		20201019

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Sunshine Biopharma, Inc
		CENTRAL INDEX KEY:			0001402328
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				205566275
		STATE OF INCORPORATION:			CO
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-52898
		FILM NUMBER:		201245263

	BUSINESS ADDRESS:	
		STREET 1:		6500 TRANS-CANADA HIGHWAY
		STREET 2:		4TH FLOOR
		CITY:			POINTE-CLAIRE
		STATE:			A8
		ZIP:			H9R 0A5
		BUSINESS PHONE:		514-426-6161

	MAIL ADDRESS:	
		STREET 1:		6500 TRANS-CANADA HIGHWAY
		STREET 2:		4TH FLOOR
		CITY:			POINTE-CLAIRE
		STATE:			A8
		ZIP:			H9R 0A5

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Mountain West Business Solutions, Inc
		DATE OF NAME CHANGE:	20071030

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	mountain west business solutions,inc
		DATE OF NAME CHANGE:	20070607
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>sbfm_8k.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<html>
<head>
<!-- Document created using Blueprint(R) - powered by Issuer Direct - www.issuerdirect.com -->
<!-- Copyright 2020 Issuer Direct Corporation -->
<title>sbfm_8k</title>
</head>
<body style="font-family: Times New Roman; font-size: 13px;">
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 8px; border-top: 4px solid #000000; border-bottom: 1px solid #000000">
<!--style header--><br></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
U.S. SECURITIES AND EXCHANGE COMMISSION</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
WASHINGTON, D.C. 20549</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-variant: small-caps; font-family: Times New Roman; font-size: 13px">
Form 8-K</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Current
Report Pursuant to Section 13 or 15(d) of</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">the
Securities Exchange Act of 1934</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Date of
Report (Date of earliest event reported):</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; font-weight: bold; font-family: Times New Roman; font-size: 13px">
October 6, 2020</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; font-weight: bold; font-family: Times New Roman; font-size: 13px">
SUNSHINE BIOPHARMA, INC.</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">(Exact
name of small business issuer as specified in its
charter)</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left">
<table cellpadding="0" cellspacing="0" style="text-align: left; width: 100%; font-family: Times New Roman; font-size: 13px; margin: 0px auto 0px 0px;">
<tr>
<td style="vertical-align: top; width: 33%; border-bottom: 2px solid #000000">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Colorado</font></div>
</td>
<td style="vertical-align: top; width: 33%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
000-52898</font></div>
</td>
<td style="vertical-align: top; width: 33%; border-bottom: 2px solid rgb(0, 0, 0);">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
20-5566275</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 33%">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">(State
or other jurisdiction</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">of
incorporation)</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">(Commission
File Number)</font></div>
</td>
<td style="vertical-align: top; width: 33%;">
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">(IRS
Employer ID No.)</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
6500 Trans-Canada Highway</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; color: #000000; font-family: Times New Roman; font-size: 13px">
4th Floor</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">
Pointe-Claire, Quebec, Canada H9R 0A5</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;(Address
of principal executive offices)</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; color: #000000; font-weight: bold; font-family: Times New Roman; font-size: 13px">
514) 426-6161</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">(Issuer&#x2019;s
Telephone Number)</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
[ ] Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="color: #000000; font-family: Times New Roman; font-size: 13px">
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (&#xA7;230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (&#xA7;240.12b-2 of this chapter).&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Emerging
growth company&#xA0;[X]</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act.
[&#xA0;&#xA0;]</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 8px; border-top: 1px solid #000000; border-bottom: 4px solid #000000">
<!--style footer--><br></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
<div id="pb" style="text-align: center; break-after: page; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: rgb(255, 255, 255);">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Item 1.01 Entry into a Material Definitive Agreement</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Effective
October 6, 2020, we entered into a Research Agreement (the
&#x201C;Agreement&#x201D;) with the University of Georgia Research
Foundation, Inc. (&#x201C;UGARF&#x201D;), a non-profit corporation
duly organized and existing under the laws of the State of Georgia,
the performance of which UGARF will subcontract to the University
of Georgia (&#x201C;UGA&#x201D;). The purpose of the Agreement is to
memorialize the terms of our working together with UGA to conduct
the necessary research and development to advance our
Anti-Coronavirus lead compound, SBFM-PL4 (or derivatives thereof)
through various stages of preclinical development, animal studies
and clinical trials for Coronavirus infections. The Agreement
grants us an exclusive worldwide license for all of the
intellectual property developed by UGA, whether alone or jointly
with us.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">All of
the work in respect of the project to be performed within the
framework of the Agreement will be financed by us. As we recently
reported (Form 8-K filed on September 15, 2020), we have executed a
Financing Agreement with RB Capital Partners, Inc., La Jolla, CA,
pursuant to which RB Capital Partners, Inc. has agreed to provide
us with a minimum of $2 million in funding for Anti-Coronavirus
drug development over the next three to six months. On September
14, 2020, we received the initial $250,000 of this
financing.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">We have
the right to terminate the Agreement at any time with a ninety (90)
day written notice. In the event such termination however, our
exclusive worldwide license will also be terminated.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Item 7.01 Regulation FD Disclosure</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Our
Press Release relating to the Agreement is attached as Exhibit 99.1
and is hereby incorporated.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Item 9.01 Financial Statements and Exhibits</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">(b)
Exhibits. The following exhibits are included in this
report:</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="display: table">
<div style="display: table-row">
<div style="display: table-cell; width: 48px"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">No.<br>
</font></div>
<div style="text-align: justify; display: table-cell"><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">Description</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="display: table">
<div style="display: table-row">
<div style="display: table-cell; width: 48px"><font style="font-family: Times New Roman; font-size: 13px"><a href="sbfm_ex991.htm">99.1</a><br></font></div>
<div style="text-align: justify; display: table-cell"><font style="font-family: Times New Roman; font-size: 13px">Press Release dated
October 19, 2020</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
<div id="pb" style="text-align: center; page-break-after: always; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">
<!--page break--></div>
<div id="hdr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
SIGNATURES</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">&#xA0;
<font style="font-family: Times New Roman; font-size: 13px"><br>
</font></div>
<div>
<table cellpadding="0" cellspacing="0" style="font-family: inherit; font-size: inherit; margin-right:0px;width:100%;margin-left:0px;">
<tr>
<td rowspan="1" style="width: 50%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td colspan="2" rowspan="1" style="vertical-align: bottom; width: 38%;">
<div><font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">SUNSHINE
BIOPHARMA, INC.</font></div>
<div><font style="font-family: Times New Roman; font-size: 13px;"><font style="font-family: Times New Roman; font-size: 13px">(Registrant)</font>&#xA0;<br>
</font></div>
</td>
<td rowspan="1" style="width: 12%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="width: 50%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 3%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 35%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 12%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="vertical-align: top; width: 50%; border-bottom: medium solid rgb(255, 255, 255);">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">Date: <font style="font-family: Times New Roman; font-size: 13px">October 19,
2020</font></font></div>
</td>
<td style="vertical-align: top; width: 3%; border-bottom: medium solid rgb(255, 255, 255);">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">By:&#xA0;&#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 35%; border-bottom: 2px solid black; white-space: nowrap;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman">/s/ <font style="font-family: Times New Roman; font-size: 13px">Dr. Steve N.
Slilaty</font> &#xA0;</font></div>
</td>
<td style="vertical-align: top; width: 12%; border-bottom: medium solid rgb(255, 255, 255);">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="width: 50%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 3%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="vertical-align: bottom; width: 35%; white-space: nowrap;">
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px"><font style="font-size: 13px; font-family: Times New Roman"><font style="font-family: Times New Roman; font-size: 13px">Dr. Steve N.
Slilaty</font> &#xA0;</font></div>
</td>
<td style="width: 12%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr><tr>
<td style="width: 50%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 3%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
<td style="width: 35%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman"><font style="font-family: Times New Roman; font-size: 13px">Chief Executive
Officer</font></font></div>
</td>
<td style="width: 12%; vertical-align: top;">
<div style="margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-size: 13px; font-family: Times New Roman">&#xA0;</font></div>
</td>
</tr></table>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">
<!--page break--></div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>sbfm_ex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<html>
<head>
<!-- Document created using Blueprint(R) - powered by Issuer Direct - www.issuerdirect.com -->
<!-- Copyright 2020 Issuer Direct Corporation -->
<title>sbfm_ex991</title>
</head>
<body style="font-family: Times New Roman; font-size: 13px;">
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="hdr">
<div style="text-align: right; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
&#xA0; <font style="font-family: Times New Roman; font-size: 13px"><font style="font-weight: bold">Exhibit 99.1</font><br></font></div>
</div>
</div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px"><img src="sbfm.jpg"></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
For Immediate Release</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
October 19, 2020</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
SUNSHINE BIOPHARMA AND UNIVERSITY OF GEORGIA TEAM UP</font></div>
<div style="text-align: center; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
TO DEVELOP A NEW ANTI-CORONAVIRUS DRUG</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Montreal,
Canada &#x2013; (ACCESSWIRE) &#x2013; Sunshine Biopharma Inc. (OTC
Markets: &#x201C;SBFM&#x201D;), a pharmaceutical company focused on
the research, development and commercialization of oncology and
antiviral drugs today announced that it has entered into an
Agreement with the University of Georgia for the purposes of
working together to advance the development of Sunshine
Biopharma&#x2019;s recently announced Anti-Coronavirus lead
compound, SBFM-PL4. The goal of this cutting-edge collaboration is
to develop SBFM-PL4, a protease inhibitor, as a treatment for
Coronavirus infections. This new treatment is based on the
technology described in Sunshine Biopharma&#x2019;s recently filed
patent application covering small molecules which can be used to
treat Coronavirus infections. Sunshine&#x2019;s SBFM-PL4, will be
put through a series of <font style="font-style: italic">in
vitro</font> tests to evaluate its specific inhibitory activity
against the SARS-CoV-2 papain-like protease (PLpro), one of two
Coronavirus encoded proteases essential for viral replication.
Following the initial <font style="font-style: italic">in
vitro</font> studies, SBFM-PL4 will be moved forward to the cell
culture testing stage and assessment in Coronavirus infected mice
before entering human clinical trials.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#x201C;We
are delighted to be working with the University of Georgia and Dr.
Scott Pegan and his team of Coronavirus experts who share our
vision of developing a treatment that would make a difference in
the fight against the pandemic,&#x201D; said Dr. Steve Slilaty, CEO
of Sunshine Biopharma.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
About Sunshine Biopharma&#x2019;s Coronavirus Treatment</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Severe
Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the
causative agent of COVID-19, the current ongoing pandemic that has
claimed the lives of over 1,000,000 people worldwide since it first
appeared in December 2019. There are currently no drugs that can
effectively arrest replication of the virus in people who have
contracted the illness. On May 22, 2020, Sunshine Biopharma filed a
provisional patent application for a library of molecules which
were designed to inhibit the Coronavirus proteases, thus shutting
down the ability of the virus to multiply and cause
illness.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
About the University of Georgia</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">As part
of its land grant tripartite mission, the University of Georgia is
committed to creating and applying new knowledge for the public
good. UGA&#x2019;s Center for Drug Discovery as well as the Colleges
of Pharmacy are excited to be a part of this ground-breaking
research related to discovery of new treatment options for
COVID-19. Profs. Scott Pegan, and David Crich will be working with
Sunshine Biopharma to spearhead the study of novel therapeutics for
the prevention and spread of COVID-19. This interdisciplinary
effort involves state of the art approaches in chemical synthesis
and drug screening. This continues University of Georgia&#x2019;s
long-standing tradition in translating scientific breakthroughs to
address real world health concerns.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
About Sunshine Biopharma</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">In
addition, to working on the development of a treatment for
COVID-19, Sunshine Biopharma is engaged in the development
Adva-27a, a unique anticancer compound. Tests conducted to date
have demonstrated the effectiveness of Adva-27a at destroying
Multidrug Resistant Cancer Cells, including Pancreatic Cancer
cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and
Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer
indication are planned to be conducted at McGill University&#x2019;s
Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is
owner of all patents and intellectual property pertaining to
Adva-27a.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; page-break-after: always; width: 100%; height: 1px; background-color: #000000">
<!--page break line--></div>
<div id="hdr">
<div style="text-align: right; width: 100%"><font style="font-family: Times New Roman; font-size: 11px">&#xA0;</font></div>
</div>
</div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px;">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Safe Harbor Forward-Looking Statements</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-style: italic; font-family: Times New Roman; font-size: 13px">
This press release may contain forward looking statements which are
based on current expectations, forecasts, and assumptions that
involve risks as well as uncertainties that could cause actual
outcomes and results to differ materially from those anticipated or
expected, including statements related to the amount and timing of
expected revenues statements related to our financial performance,
expected income, distributions, and future growth for upcoming
quarterly and annual periods. These risks and uncertainties are
further defined in filings and reports by the Company with the U.S.
Securities and Exchange Commission (SEC).&#xA0; Actual results and
the timing of certain events could differ materially from those
projected in or contemplated by the forward-looking statements due
to a number of factors detailed from time to time in our filings
with the SEC. Among other matters, the Company may not be able to
sustain growth or achieve profitability based upon many factors
including but not limited to general stock market conditions.
Reference is hereby made to cautionary statements set forth in the
Company's most recent SEC filings. We have incurred and will
continue to incur significant expenses in our expansion of our
existing as well as new service lines noting there is no assurance
that we will generate enough revenues to offset those costs in both
the near and long term.&#xA0; Additional service offerings may
expose us to additional legal and regulatory costs and unknown
exposure(s) based upon the various geopolitical locations we will
be providing services in, the impact of which cannot be predicted
at this time.</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
For Additional Information:</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-weight: bold; font-family: Times New Roman; font-size: 13px">
Sunshine Biopharma, Inc.</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Camille
Sebaaly, CFO</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">Direct
Line: 514-814-0464</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; color: #0000FF; font-family: Times New Roman; font-size: 13px">
camille.sebaaly@sunshinebiopharma.com</font></div>
<div style="text-align: left; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="text-decoration: underline; color: #0000FF; font-family: Times New Roman; font-size: 13px">
www.sunshinebiopharma.com</font></div>
<div style="text-align: justify; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
<div id="pgbrk" style="width: 100%; margin-left: 0px; text-indent: 0px; margin-right: 0px">
<div id="ftr">
<div style="text-align: left; width: 100%; margin-left: 0px; margin-right: 0px; text-indent: 0px">
<font style="font-family: Times New Roman; font-size: 13px">&#xA0;</font></div>
</div>
<div id="pb" style="text-align: center; margin-left: 0px; margin-right: 0px; margin-bottom: 6px; width: 100%; height: 1px; background-color: #000000">
<!--page break--></div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>sbfm.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 sbfm.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 Z17AI9@  34T *@    @  U$0  $
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M-_QLSOHU%."T&^>__/ T>>__ #P-/\R7_GB?S%'F2_\ /$_F*Y+R_P"?DO\
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H* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
